Specialty Drug Prices and Utilization after Loss of U.S. Patent Exclusivity, 2001-2007
This chapter is a preliminary draft unless otherwise noted. It may not have been subjected to the formal review process of the NBER. This page will be updated as the chapter is revised.
Chapter in forthcoming NBER book Measuring and Modeling Health Care Costs, Ana Aizcorbe, Colin Baker, Ernst Berndt, and David Cutler, editors
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007, Rena M. Conti, Ernst R. Berndt